About: MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.61 (-2.42%)
MNOV NASDAQ MediciNova Inc
MediciNova Inc share price
MNOV price activity
Último preço
$ 1,610
Variação (24h)
-0,04 USD (-2,42%)
Volume
77.97K
Volume (média 4 sem.)
-
Abertura
$ 1,65
Variação do dia
$ 1,60 - $ 1,65
Fechamento anterior
$ 1,65
Último negócio
07 Oct, 8:00 pm GMT+0
Atrasado
07 Oct, 8:00 pm GMT+0
MNOV price performance
Atrasado
07 Oct, 8:00 pm GMT+0
quote.marketSignals